Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
&NA; Insulin resistance (IR) is a metabolic state preceding development of type 2 diabetes (DM2), cardiovascular disease, and neurodegenerative disorders, including Alzheimer's Disease (AD). Liraglutide, a glucagon‐like peptide‐1 (GLP) agonist, is an insulin‐sensitizing agent with neuroprotective properties, as shown in animal studies. The purpose of this double‐blinded, placebo‐controlled study was to examine the neural effects of administration of liraglutide in cognitively normal late middle‐aged individuals with subjective cognitive complaints (half of subjects had family history of AD). Seed‐based resting state connectivity using functional magnetic resonance imaging (fMRI) was conducted before and after 12 weeks of liraglutide treatment or placebo. Neuropsychological testing was conducted before and after treatment to determine whether there were any potential behavioral correlates to neural changes. Results: At baseline (time point 1), higher fasting plasma glucose (FPG) was associated with decreased connectivity between bilateral hippocampal and anterior medial frontal structures. At time point 2, we observed significant improvement in intrinsic connectivity within the default mode network (DMN) in the active group relative to placebo. There were no detectable cognitive differences between study groups after this duration of treatment. To our knowledge, this is the first placebo‐controlled study to report neural effects of liraglutide in a middle‐aged population with subjective cognitive complaints. Larger and longer duration studies are warranted to determine whether liraglutide has neuroprotective benefits in individuals at risk for AD. HighlightsLiraglutide improves intrinsic connectivity within default mode network.Baseline fasting glucose associated with greater connectivity.No cognitive differences found after liraglutide treatment compared to placebo.Liraglutide may be neuroprotective in individuals at risk for Alzheimer's Disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.10.018 · Cited by 7,429
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 1×
“Decreased DMN function has been demonstrated in patients with AD [43], in individuals with prodromal AD [10], in healthy individuals with high amyloid burden [44], and in postmenopausal women with IR and genetic risk for AD [39].”
Self-citationCluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
Eklund, A., Nichols, T. E., & Knutsson, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602413113 · Cited by 3,487 · cited 1×
“0, corrected for multiple comparisons) may have resulted in false-positives [52].”
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“Such speculation would be consistent with the previous reports of improvements in connectivity often preceding improvement in cognitive performance [50,51].”
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Sheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597
Vagelatos, N. T., & Eslick, G. D. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs012 · Cited by 320
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“In a double blind placebo controlled study, 12 week treatment with liraglutide in patients at risk for AD did not show cognitive differences between the study cohorts [838].”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“In another trial with non-diabetes subjects at increased risk of Alzheimer’s disease, administration of liraglutide for 3 months improved brain region connectivity (assessed by functional MRI), but cognitive functions did not improve [225].”
BackgroundAstrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Beard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 302
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Metadata
- Authors
- Watson, K. T., Wroolie, T. E., Tong, G., Foland-Ross, L. C., Frangou, S., Singh, M., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., & Rasgon, N. L.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 356
- Pages
- 271-278
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W2887818584
- Cited by
- 134
- References
- 12
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.bbr.2018.08.006
- The paper
- Watson, K. T., Wroolie, T. E., Tong, G., Foland-Ross, L. C., Frangou, S., Singh, M., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., & Rasgon, N. L. (2019). Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2018.08.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.